• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    2014 a Bad Year for Public Health; 2015 Unlikely to Differ

    Written by Charlotte McLeod
    |
    Dec. 19, 2014 08:50AM PST

    The Associated Press reported that 2014 was a “black-eye year for public health” due to a variety of mishaps, including “vital vaccines” failing to work and the worst-ever Ebola epidemic.

    The Associated Press reported that 2014 was a “black-eye year for public health” due to a variety of mishaps, including “vital vaccines” failing to work and the worst-ever Ebola epidemic. And while there were some success stories, some believe the future doesn’t look particularly bright.

    As quoted in the market news:

    Infectious diseases are a continuing threat, and no one should think of 2014 as an aberration, said Michael Osterholm, a University of Minnesota infectious disease expert.

    ‘I think what we really hit is a new normal,’ he said.

    Indeed, it could get worse. Osterholm noted that Ebola and MERS barely touched the U.S. this year, and worrisome forms of influenza in Asia and elsewhere may be on the horizon. Arrivals of people from overseas — and whatever germs they’re carrying — are forecast to keep growing. And adding to the threat of new bugs is the revived menace from old ones, as once-treatable germs are increasingly becoming resistant to antibiotics, experts said.

    Click here to read the full report from the Associated Press.

    infectious disease
    The Conversation (0)

    Go Deeper

    AI Powered
    Scientist pouring blue liquid from a test tube into a flask in a lab.

    Biotech Market Forecast: Top Trends for Biotech in 2026

    Life Science Outlook: World Edition

    Life Science Outlook: World Edition

    Latest News

    BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

    Appendix 4C Cashflow Statementand Quarterly Activities Report

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES